Skip to Main Content

Five years ago, Companion DX Reference Lab hoped to cash in on cutting-edge genetic tests paid for by Medicare.

The Houston lab marketed a test to assess how a person’s genes affect tolerance for drugs such as opiates used to treat chronic pain. It also ran DNA tests to help treat cancer and urine screens to monitor drug abuse.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Pierce the corporate shell & go after the assets of the top officers of these companies… Big Pharma CEOs & their lobbyists are skimming off the profits from hyped up testings & perscriptions that have 100s times markup over costs to produce…

Comments are closed.